Plné znění - 2/2008 Sb. m. s.

Xxxxxxxxxxxx zahraničních xxxx sděluje, xx xxx 16. xxxxxxxxx 2007 xxxx generálním xxxxxxxxx UNESCO, xxxxxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx sportu¹⁾, xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy I - Xxxxxxx zakázaných látek x xxxxx xxxxxxx.

Xxxxxxx I vstoupila x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2008 a xxxxx xxxx vstoupila x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx Xxxxxxx X Xxxxxxxxxxx úmluvy proti xxxxxxx xx xxxxxx xx znění xxx xxx 2007, vyhlášená xxx č. 59/2007 Xx. m. x.

Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx xxxxxxx xxxxxx se xxxxxxxxx xxxxxxxx.

X1. ANABOLICKÉ LÁTKY

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. ANDROGENNÍ XXXXXXXXXX XXXXXXXX (AAS):

x. Exogenní * XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (19-xxxxxxxxxxxxxxxx); bolasteron; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-xxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-nor-17α-pregn-4-en-17-ol); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; metandienon (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxx; nandrolon; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; oxymetolon; xxxxxxxxxxx ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

x. Xxxxxxxxx ** AAS:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx x xxxxxxx:

5α-xxxxxxxxx-3α,17α-xxxx xxxxxxx-5-xx-3β,17α-xxxx

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)

5α-xxxxxxxxx-3β,17α-xxxx 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

5α-androstan-3β,17β-diol epi-dihydrotestosteron

androst-4-en-3α,17α-diol 3α-hydroxy-5αandrostan-17-on

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

androst-5-en-3β,17α-diol 19-norandrosteron

xxxxxxx-5-xx-3α,17α-xxxx 19-xxxxxxxxxxxxxxxxx

xxxxxxx-5-xx-3α,17β-xxxx

V xxxxxxxxx, kdy může xxxx xxxxxxxxxx androgenní xxxxxxxxxx xxxxxxx xxxxxxxxx, xxxx xx xxx xx xx, xx Xxxxxx obsahuje xxxx Xxxxxxxxx xxxxx a xxxx hlášen xxxxxxxxx Xxxxxxxxx laboratorní xxxxx, xxxx xx xxxxxxxxxxx Xxxxxxxx látky xxxx xxxxxx xxxxxxxxxx xxxx xxxxxxxxxxx a/nebo xxxx xx xxxxxxxx jiný xxxxxxxxx xxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxx, které se xxxxxxxx xxxxxxxxx u xxxx xxx, xx xxxxxxxxxx normální endogenní xxxxxxxx. Xxxxxx xx xxx xx to, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx x xxxxxxx případě, xxxxx Xxxxxxxxx prokáže, že xx koncentrace Zakázané xxxxx xxxx xxxxxx xxxxxxxxxx xxxx xxxxxxxxxx x/xxxx xxxxxxxxx xxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx fyziologickým xxxx xxxxxxxxxxxx stavem.

Xxxx xx xxx xx xx, že Xxxxxx Xxxxxxxxx xxxxxxxx Xxxxxxxxx xxxxx x xxxxxxxxx xxxxxxx Xxxxxxxxx laboratorní xxxxx xx xxxxx xxxxxxxxx x xxx xxxxxxxxx koncentraci, pokud xxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) prokázat, že xx Xxxxxxxx látka xxxxxxxxxx xxxxxx. X xxxxxxx xxxxxxx xxxx xxxxx xxxxxxxx další xxxxxxx.

Xxxx xx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxx, které xx xxxxxxxx xxxxxxxxx x xxxx a xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx exogenní původ Xxxxxxxx xxxxx, ale xxxxxxxx xxxxxx použití Xxxxxxxx xxxxx, xxxx xxxx. xxxxxxxxx x xxxxxxxxxxx referenčními steroidními xxxxxxx, nebo když xxxxxxxxx xxxxxxxxx poměr X/X xxxxx xxx xxxxx (4) ku xxxxx (1) a xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. IRMS) xxxxxxxxxxx xxxxxxxx xxxxx xxxxx, provede xxxxxxxxx Xxxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx porovnáním xxxxxxxx xxxxxxxxxx xxxxx xxxx xxxxxxxxxx následných testů.

Xx-xx xxxxxxxxxx takové xxxxx xxxxxxx, xxx xxxxxxxx xxxx xxxxxxxxxx xxxxxx jako neobvyklý x xx xxxx xxxxxxxxx. Xxxxx xxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxxxx analytické xxxxxx (xxxx. XXXX) exogenní xxxxx Zakázané xxxxx, xxxx xxxxx xxxxxxxx xxxxx xxxxxxx, x xxxx se xxx xx xx, xx Xxxxxx obsahuje Zakázanou xxxxx. Xxxxx xxxxxx xxxxxxx spolehlivá xxxxxxxxxx xxxxxx (xxxx. XXXX) x xxxxxx x xxxxxxxxx minimálně 3 xxxxxxxxx xxxxx, xxxx xxxxxxx xxxxxxxxxxxxxx xxxxxx Xxxxxxxxx xxx, xx xxxx příslušnou Xxxxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxxxxxx 3 xxxxxxxx třikrát xxxxxxxx bez xxxxxxxxxxx xxxxxxxx. Xxxxxxxx, který xxxxxxxxxx tuto xxxxxxxxxxxxxx xxxxxx, xxxx xxxxxx xxxx xxxxxxxxx. Xxxxx xxxxxxxxxxxxxx xxxxxx Xxxxxxxxx, xxxxxxxx xxxxxxxxxx xxxxx, xxxx xxxxxxxxxxxx xxxxxxxx, xxxx xx pak xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx.

V xxxxxxxx xxxxxxxx individuálních xxxxxxxxx může být x moči trvale xxxxxxx xxxxxxxx endogenního xxxxxx xx xxxxxx xxxxxx xxxxxxxxxxxxx (ng/ml). Xxxxx xxxxxxxxx takový xxxxx nahlásila a xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (např. IRMS) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx látky, xxxx xxx provedeno další xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx (xxxxxxxxxx xxxxx).

Xxxxx laboratoř xxxxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx 19-xxxxxxxxxxxxxxx, bude xx xx považovat xx xxxxxxx x xxxxxxxxxxx xxxxx xxxxxxxxxx původu Xxxxxxxx látky. V xxxxxxx xxxxxxx xxxx xxxxx xxxxxxxx další xxxxxxx.

V xxxxxxx, xx Xxxxxxxxx xxxxxx xxxxxxxxxxxxx xxx dalších xxxxxxxxx, xxxx xx xxx za xx, xx Xxxxxx Sportovce xxxxxxxx Xxxxxxxxx xxxxx.

2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.

S2. XXXXXXX A XXXXXXXX XXXXX

Xxxxxxxxxxx xxxxx x jejich uvolňující xxxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxx (EPO);

2. Xxxxxxx hormon (xXX), insulinu podobné xxxxxxx faktory (xxxx. XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX);

3. Xxxxxxxxxxxxx (xxxx. XX, xXX), xxxxxxxx jen x xxxx;

4. Xxxxxxxx;

5. Kortikotropiny

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Pokud Xxxxxxxxx nemůže xxxxxxxx, xx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx či xxxxxxxxxxxx xxxxxx, xxxx xx mít xx xx, že Vzorek xxxxxxxx Xxxxxxxxx xxxxx (xxx xx uvedeno xxxx) v xxxxxxxxx, xxx koncentrace Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx xx xxxxxxxxxx x/xxxx xxxxxxxxx xxxxxx xx Xxxxxx Sportovce xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxxxx x xxxx xxx, xx xxxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx.

Xxxxx xxxxxxxxx xxxxxxxxx, po xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx, xx Xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxx, xxxx xx xxx xx to, xx Xxxxxx xxxxxxxx Zakázanou xxxxx a xxxx xxxxxxx Pozitivní laboratorní xxxxx.

X3. XXXX-2 XXXXXXXX

Xxxxxxx xxxx-2 xxxxxxxx včetně xxxxxx X- x X-xxxxxxx xxxx xxxxxxxx.

Xxxxxxxx xxxx formoterol, xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxx, pro xxxxx xx xxx xxxxxxxx xxxxx udělení zkrácené xxxxxxxxxxxx výjimky.

I xxxx xxxx xxxxxxx xxxxxxxx xxxxx terapeutické xxxxxxx, xxxx xxxxx xxxxxxxxxxx (xxxxx plus xxxxxxxxxx) vyšší než 1000 xxxxxxxxx x 1 xxxxxxxxx xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx xxxxxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx terapeutickým xxxxxxxx xxxxxxxxxxx v xxxxxxxx.

X4. ANTAGONISTÉ X XXXXXXXXXX XXXXXXX

Xxxxxxxxxxx skupiny jsou xxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, zahrnující:

2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SERM), xxxxxxxx:

3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:

4. Xxxxx modifikující xxxxxx xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, xxx xx x omezením pouze xx xx.

X5. XXXXXXXXX A XXXXXXX MASKOVACÍ LÁTKY

Xxxxxxxxx xxxxx xxxx xxxxxxxx. Zahrnují:

Xxxxxxxxx*, epitestosteron, xxxxxxxxxx, xxxxxxxxxx alfa-reduktázy (xxxx. xxxxxxxxxx, xxxxxxxxxx), xxxxxxxxxxxxxxx (xxxx. xxxxxxx, xxxxxxx, xxxxxxxxxxxxxxxxx) x xxxxx xxxxx x podobnými xxxxxxxxxxxx xxxxxx.

Diuretika xxxxxxxx:

Acetazolamid, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, kanrenon, kyselina xxxxxxxxxx, metolazon, xxxxxxxxxxxxx, xxxxxxxx (např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx).

* Xxxxxxxxxxxx xxxxxxx není xxxxxx, xxxxx xxx Xxxxxxxxx xxxxxxxx diuretika xx xxxxxxx x xxxxxxxx xxxx podprahovou xxxxxxxx xxxx Xxxxxxxx xxxxx (xxxxx).

X1. XXXXXXXXX XXXXXXX XXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X2. XXXXXXXX X FYZIKÁLNÍ MANIPULACE

M3. XXXXXX DOPING

Xxxxxxxxxxxxxx xxxxxxx xxxxx, xxxx, xxxxxxxx elementů, xxxx xxxxxxxxxx xxxxxxx xxxx, xxxxx xxxx schopnost xxxxxx xxxxxxxxx výkon, xx xxxxxxxx.

X6. STIMULANCIA

Xxxxxxx xxxxxxxxxxx (včetně xxxx xxxxxx xxxxxxxxxx optických (X- x L-) xxxxxxx) xxxx xxxxxxxx, x výjimkou xxxxxxxx xxxxxxxxx v xxxxxxx xxxxxx xxxxxxxx xxxxx x stimulancií xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx xxx 2008.

Xxxxxxxxxxx xxxxxxxx:

Xxxxxxxxx, xxxxxxxxx**, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, cyklazodon, xxxxxxxxxxxxxxxxx, xxxxxxx****, etamivan, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxx***, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, krotetamid, levmetamfetamin, xxxxxxxxx, mefentermin, xxxxxxxxxxxx, xxxxxxxxxxxx (X-), xxxxxxxxxxxx****, xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, oktopamin, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, pentetrazol, p-methylamfetamin, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, tuaminoheptan x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

Xxxxxxxxxxxx xxxxxxxxx výslovně xxxx příklady v xxxxx xxxxxx bude xxxxxxxxxx xx specifickou xxxxx xxxxx, pokud Xxxxxxxxx xxxxxxx, xx xxxx všeobecná dostupnost x běžných xxxxxxxxx xxxxxxxxxxx xxxxxxxx neúmyslné xxxxxxxx antidopingových pravidel, xxxx xx x xxx xxxxx xxxxxxxxxxxxxxx, xx xxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxx xxxxx.

X7. XXXXXXXXX

Následující xxxxxxxxx xxxx zakázaná:

Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, pentazocin, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx (xxxx. xxxxx, marihuana) jsou xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx xxxx nitrosvalovou xxxxxxxx xxxx xxxxxxxx. Xxxxxx xxxxx xxxxxxxx xxxxxxxxxxxxx xxxxxxx.

Xxxx xxxxxxx xxxxxxxx xxxxxxxx (xxxxxxxxxxxx, xx xxxxx xxxxxx, xx xxxxx xxxxxx, xxxxxxxxxx, do xxxx) x xxxxxxxxx xxxxxxxx xxxxxxxx zkrácenou xxxxxxxxxxxxx výjimku x xxxxxxxx xxxx uvedených.

Xxxxxxx přípravky xxxxxxxx xx xxxxxx xxxxx (xxxxxx xxxxxxxxxxx/xxxxxxxxxx), xxxx, xxxxx, oční, potíže xxxxx řitního xxxxxx, xxxxxxxx xxx a xxxxx nejsou xxxxxxxx x nevyžadují xxxxxx xxxxx xxxxxxxxxxxx xxxxxxx.

X1. XXXXXXX

Alkohol (xxxxxx) xx zakázaný pouze Xxx xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx bude xxxxxxxx xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) je pro xxxxxx xxxxxxxx uvedena x xxxxxxxxx.

∙ Xxxxxxxxxxxx xxxxx (FIA) (0.10 x/x)

∙ Xxxxxx (WKF) (0.10 x/x)

∙ Xxxxxxx xxxxxx x parašutismus (XXX) (0.20 x/x)

∙ Lukostřelba (XXXX, XXX) (0.10 g/l)

∙ Moderní xxxxxxx (XXXX) jen xxx xxxxxxxxxx xx xxxxxxxx (0.10 g/l)

∙ Xxxxxxxxxxx xxxxx (XXX) (0.10 g/l)

∙ Vodní motorismus (XXX) (0.30 g/l)

∙ Xxxxxxx (XXX) (0.10 g/l)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Při xxxxxxx x následujících xxxxxxxx.

∙ Xxxxxxxxxxxx xxxxx (XXX)

∙ Billiard (XXXX)

∙ Xxxx (XXXX)

∙ Bridž (XXX)

∙ Xxxxxxx (XXX)

∙ Xxxxxxxxxx (XXX)

∙ Jachting (XXXX) - "xxxxx xxxx" - xxx xxxxxxxxxxx

∙ Xxxxxxx (XXX)

∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX)

∙ Xxxxxxxxxxx (XXXX, IPC) (zakázané xxxx Xxxx xxxxxx)

∙ Xxxxxxxx (FIS) - xxxxx xx xxxxxx x akrobatické xxxxxxxx-xxxxx x U-rampa, x snowboard X-xxxxx x "big xxx"

∙ Xxxxxxx xxxxxxx (XXXX) - xxx xxxxxxxxxx xx xxxxxxxx

∙ Xxxxxxxxxxx xxxxx (XXX)

∙ Petanque x xxxxxxx xxxxxx (XXXX, IPC "xxxxx")

∙ Střelba (ISSF, XXX) (zakázané xxxx Xxxx soutěž)

∙ Xxxxx motorismus (UIM)

∙ Xxxxx (XXXX)

Xxxx-xxxxxxxxx zahrnují xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, betaxolol, bisoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, sotalol, xxxxxxx, xxx xx x xxxxxxxx xxxxx na xx

"Xxxxxxxxxx látky"* xxxx xxxxxxxxxxx xxxx:

∙ Všichni Xxxx-2 xxxxxxxx v inhalaci, xxxxx xxxxxxxxxxx (xxxxxxx xxxx xxxxxxxxxxx) při xxxxxxxx větším xxx 1000 xx/xx xxxx x clenbuterolu (xxxxxxx xx xxxxxxx X 1.2 Ostatní xxxxxxxxxx xxxxx);

∙ Inhibitory xxxx-xxxxxxxxx, probenecid;

∙ Xxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxx, famprofazon, xxxxxxxxxxxxx, haptaminol, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, norfenefrin, xxxxxxxxx, ortetamin, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxx xxxxxxx stimulancia xxxxxxxxx xxxxxxxx x xxxxxx X6, xxx xxxxx Xxxxxxxxx xxxxxxx, že xxxxxxx xxxxxxxx popsané x xxxxxx S6;

∙ Xxxxxxxxxxx;

∙ Xxxxxxx Xxxxxxxxxxxxxxxxxxxx;

∙ Xxxxxxx;

∙ Xxxxxxx Xxxx-xxxxxxxxx.

*"V Seznamu xxxxx být xxxxxxxxxxx xxxxxxxxxx látky, které xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx pravidel, xxxxxxx xxxx xxxxxxxxx xxxxxxxx x běžných xxxxxxxxx přípravcích, xxxx x xxxxx je xxxxx xxxxxxxxxxxxxxx, xx xxxxx úspěšně xxxxxxxx xxxx xxxxxxxxx xxxxxxx." Xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx takovéto látky xxxx xxxxxxxx xxxxxxx xxxxxx za xxxxxxxxxxx, xx "...Sportovec xxxx xxxxx xxxxxxxx, xx Xxxxxxx specifické xxxxx xxxxxx zamýšleno ke xxxxxxx xxxxxxxxxxx xxxxxx...".

Xxxxxx xxxxxxx x. 2/2008 Xx. m. x. xxxxx xxxxxxxxx xxxx 31.1.2008.

Xxxxxx xxxxxxx č. 2/2008 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 8/2009 Sb. m. s. x xxxxxxxxx xx 7.2.2009.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx.